SCHEMBL15094936

SCHEMBL15094936

CCNC(=O)Nc1nc(Nc2ccccc2)nc(-c2ccccc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH2 P48735 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.48
▸ RHOA P61586 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.45
▸ PIK3CA P42336 1/20 0.45
▸ MTOR P42345 1/20 0.45
▸ PIK3CG P48736 1/20 0.45
▸ TP53 P04637 1/20 0.44
▸ ABL1 P00519 2/20 0.44
▸ CA12 O43570 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ PDE4B Q07343 2/20 0.43
▸ PDE4D Q08499 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15102600 0.84 ADORA3 (0.59) IDH2ALDH1A1RHOAKDM4EMEN1
SCHEMBL15094720 0.82 IDH2 (0.59) IDH2ALDH1A1RHOANPSR1CA12
SCHEMBL15102519 0.81 LMNA (0.54) IDH2ALDH1A1RHOANPSR1TP53
SCHEMBL16391764 0.81 ABCG2 (0.55) PIK3CAABL1MEN1KMT2ANPC1
SCHEMBL15124116 0.80 IDH2 (0.57) IDH2ALDH1A1RHOANPSR1TP53
SCHEMBL15094812 0.80 IDH2 (0.54) IDH2ALDH1A1RHOANPSR1PDE4B
SCHEMBL11917263 0.80 AURKB (0.47) PIK3CAMTORPIK3CGABL1
SCHEMBL15094752 0.78 IDH2 (0.56) IDH2ALDH1A1RHOANPSR1TP53
SCHEMBL15102360 0.78 ADORA1 (0.59) IDH2ALDH1A1RHOANPSR1TP53
SCHEMBL29763445 0.78 IDH2 (0.63) IDH2ALDH1A1RHOANPSR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647076-A2 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Les Laboratoires Servier (FR) 2025-11-12 — — EP disclosed
EP-3984997-B1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER LAB (FR) 2025-07-30 — — EP disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed
CN-115536635-A Therapeutically active compounds and methods of use thereof 法国施维雅药厂 2022-12-30 — — CN disclosed
CN-115521264-A Therapeutically active compounds and methods of use thereof 法国施维雅药厂 2022-12-27 — — CN disclosed
US-11505538-B1 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2022-11-22 — — US disclosed
US-11505538-B1 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2022-11-22 — — US disclosed
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2022-11-03 — — US disclosed
US-20160318903-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-11-03 — — US disclosed
US-20160318903-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-11-03 — — US disclosed
US-20160318903-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-11-03 — — US disclosed
EP-2800743-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Agios Pharmaceuticals, Inc. (US) 2014-11-12 — — EP disclosed
CN-104114543-A Therapeutically active compounds and methods of use thereof AGIOS PHARMACEUTICALS INC 2014-10-22 — — CN disclosed
US-20130190287-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-25 — — US disclosed
US-20130190287-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-25 — — US disclosed
US-20130190287-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-25 — — US disclosed
WO-2013102431-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-11 — — WO disclosed
WO-2013102431-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT IDH2 110/4885ALDH1A1 923/4885RHOA 304/4885
US-20160318903-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE MCL1, TP53, MMP8 IDH2 203/4885ALDH1A1 1337/4885RHOA 118/4885
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT IDH2 110/4885ALDH1A1 923/4885RHOA 304/4885
US-11505538-B1 Therapeutically active compounds and their methods of use MCL1, TP53, BRDT IDH2 110/4885ALDH1A1 923/4885RHOA 304/4885
US-20130190287-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT IDH2 110/4885ALDH1A1 923/4885RHOA 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback